Monopar Therapeutics MNPR Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $230.43K.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's total debt?
- Monopar Therapeutics (MNPR) reported total debt of $230.43K in Q1 2026.
- How has Monopar Therapeutics's total debt changed year-over-year?
- Monopar Therapeutics's total debt increased by 2692.4% year-over-year, from $8.25K to $230.43K.
- What is the long-term trend for Monopar Therapeutics's total debt?
- Over 2 years (2022 to 2025), Monopar Therapeutics's total debt has grown at a 107.5% compound annual growth rate (CAGR), from $56.99K to $245.49K.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.